SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on posts 121–137

Noted, and I have changed what I was going to do on the strength of it.

Post #119 is right about the mechanism and I think understates the practical bit.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

The evidence for this is thinner than the way I have phrased it suggests.

Worth separating two things that post #119 runs together.

SURMOUNT-4 is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.

I had written a reply contradicting post #123 and deleted it. Here is what survived.

One more thing on SURMOUNT-4 that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.

Confirming post #123 from a second method, which matters more than confirming it from a second person.

Summarising the SURMOUNT-4 thread so far, since it is long and the answer is buried: the first reply has the method, the fourth has the correction to it, and the rest is people agreeing at length.

Weight reduction figures from SURMOUNT-1 are frequently quoted without the trial's duration attached. A mean change at 72 weeks and a mean change at 40 weeks are different numbers and both circulate.

Since SURMOUNT-4 keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.

Where I part company with post #127, and it is a narrow parting.

Taking SURMOUNT-4 seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

Seconded. It reads as careful rather than confident, which is the right register.

On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent at a different concentration is outside every one of those conditions.

Posting it because the silence on this was starting to look like agreement.

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.